Table 3.
Bivariable HR (95% CI)* | Multivariable HR (95% CI)* | |
---|---|---|
Age (years) | ||
18–49 | Reference | Reference |
50–64 | 0.98 (0.67–1.45) | 0.93 (0.62–1.40) |
65–74 | 0.78 (0.51–1.18) | 0.84 (0.54–1.30) |
≥ 75 | 1.54 (1.03–2.30) | 1.36 (0.89–2.07) |
Female sex | 0.99 (0.62–1.59) | 1.32 (1.02–1.71) |
Race | ||
White | Reference | |
African-American | 1.11 (0.82–1.50) | |
Asian-American | 0.89 (0.55–1.42) | |
Hispanic ethnicity | ||
Yes | 1.07 (0.75–1.53) | |
Charlson-Deyo score | ||
0 | Reference | Reference |
1 | 1.57 (1.17–2.09) | 1.41 (1.05–1.90) |
≥ 2 | 1.13 (0.72–1.75) | 1.29 (0.74–1.92) |
Gastrectomy type | ||
Subtotal | Reference | |
Total | 1.12 (0.86–1.45) | |
Gastrectomy unspecified | 1.05 (0.72–1.55) | |
MVR | ||
Yes | 0.75 (0.47–1.20) | |
Primary tumor stage | ||
T4b | 1.17 (0.92–1.49) | |
Pathologic nodal stage | ||
0 | Reference | Reference |
1 | 1.36 (0.90–2.06) | 1.61 (1.06–2.47) |
2 | 1.18 (0.79–1.76) | 1.45 (0.96–2.19) |
3 | 2.35 (1.69–3.27) | 2.69 (1.91–3.78) |
Neoadjuvant chemotherapy | ||
Yes | 0.88 (0.66–1.16) | |
Neoadjuvant radiation | ||
Yes | 0.72 (0.27–1.94) | |
Adjuvant chemotherapy | ||
Yes | 0.59 (0.46–0.75) | 0.75 (0.55–1.03) |
Adjuvant radiation | ||
Yes | 0.64 (0.49–0.84) | 0.77 (0.55–1.08) |
Hazard ratios and 95% confidence intervals